spacer
home > ict > spring 2015 > thinking allowed
PUBLICATIONS
International Clinical Trials

Thinking Allowed


ICT
: Validation is a long-standing concern for ePRO – how much of an issue is it for trials today?


Emily Cantrell: ePRO often provides higher quality data, but it can be a challenge to implement. If you are using ePRO for a pivotal trial or the data is likely to be used in a marketing application submission, it is likely that validation will be necessary. In addition, if you are using ePRO to collect your primary endpoint, validation may be needed.

Validation costs are typically not included in bids from ePRO vendors. A third-party vendor is often required to perform the validation and the costs can be significant – at more than $50,000 – so be sure to budget accordingly.

What are the key considerations for implementing ePRO and smart devices in studies?

We would give three key tips. Firstly, determine early in the site feasibility and qualification process if sites are prepared to use ePRO. Look for potential issues during the site qualification visit, so you can address them early in the study. Secondly, training is critical for the study team, site staff and investigators. Make sure everyone is comfortable using the devices involved. Finally, have a paper-based back-up system and understand how paper data will be transferred to the ePRO system. Be clear during training under what conditions sites should utilise paper back-ups.

You recently carried out a large trial using tablets for ePRO – tell us more.

Over the past 18 months, we have been working on a study that utilises ePRO on tablet devices for a large Phase 3 pain trial. The devices were kept at the sites and participating subjects only entered data during study visits. For other studies that use ePRO for diary data (where subjects take the devices home and enter data on their own), specific training plans need to be devised with sites for their subjects, but this makes for a trickier plan.

What study and site issues did you encounter?

The devil was in the detail. Validation costs were not included in the ePRO vendor’s bid; they were an additional cost we were not expecting. A number of sites did not have reliable Wi-Fi access, so we ended up providing mobile Wi-Fi hotspots. Also, our vendor made a decision to upgrade devices and change its stylus between when we signed the work order and our study going live, which created some logistical headaches.

What ePRO lessons did this study flag up?

Based on our experience, we would advise the following. Carefully review vendor bids to make sure everything you need is included. Make sure sites are prepared, with Wi-Fi access, a place to store and charge the devices, and staff who are comfortable using the system. Provide thorough hands-on training to the study team, site personnel and investigators.

We would also recommend being involved in user acceptance testing, and to consider how support will be provided. In our case, we provided frontline support, rather than directing all calls to the ePRO vendor.

Where do you see ePRO heading over the next decade?

As more studies and sites use ePRO and become familiar with it, a wider adoption should develop. Hopefully, device costs will decline and a library of common forms will become available versus building each study from scratch. More robust solutions for uploading data should be introduced, which will help too.

We have received feedback that older subjects are less comfortable with using tablets and the technology that goes with them. In the decade ahead, a generation more familiar with technology will be moving into clinical research studies – and this will evolve ePRO further.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emily Cantrell is Senior Director, Operations at full-service CRO, Rho. She has extensive experience managing clinical trials in a number of therapeutic areas, and recently served as the Project Advisor for a large Phase 3 pain study using ePRO with tablet devices.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

How To Increase Efficiency, Customer Satisfaction and Reduce Cost

AC Labels

A customer of Riverside Medical had required a complex four-part 'piggy back' label. The labels needed to be specially constructed to facilitate removal in parts at various stages of its use for quality control traceability. This label needed to carry variable data elements of LOT numbers, batch numbers and product descriptions, and also a secondary gamma indicator label placed on each of its 4 sections to prove its sterility following sterilisation.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement